The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial

Hajihashemi, Parisa; Askari, Gholamreza; Khorvash, Fariborz; Maracy, Mohammad Reza; Nourian, Mojgan

doi:10.1177/0333102418821661

Cited by 57 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results indicated a significant reduction in the levels of lactate (-2.28 mg/dl, 95% CI: -3.65, -0.90; p = .002), severity (-3.03, 95% CI: -3.65, -2.40; p ≤ .001), duration (-7.67, 95% CI: -11.47, -3.90; p ≤ .001), and frequency (-5.42, 95% CI: -7.31, -3.53; p ≤ .001) after eight weeks [38]. These findings suggest that co-administration of CoQ10/L-carnitine supplements results in the improvement of severity, duration, and frequency of migraine attacks [38]. Furthermore, this combined therapy can also help reduce serum lactate levels in migraine patients [38].…”

Section: L-carnitinementioning

confidence: 99%

“…Conversely, when compared to placebo, Hagen et al provided no statistically significant difference and benefit from acetyl-l-carnitine administration (3 g/day) [37]. Hajihashemi et al studied the efficacy of concurrent administration of CoQ10 (30 mg/day) and L-carnitine (500 mg/day) supplementation [38]. The results indicated a significant reduction in the levels of lactate (-2.28 mg/dl, 95% CI: -3.65, -0.90; p = .002), severity (-3.03, 95% CI: -3.65, -2.40; p ≤ .001), duration (-7.67, 95% CI: -11.47, -3.90; p ≤ .001), and frequency (-5.42, 95% CI: -7.31, -3.53; p ≤ .001) after eight weeks [38].…”

Section: L-carnitinementioning

confidence: 99%

“…Hajihashemi et al studied the efficacy of concurrent administration of CoQ10 (30 mg/day) and L-carnitine (500 mg/day) supplementation [38]. The results indicated a significant reduction in the levels of lactate (-2.28 mg/dl, 95% CI: -3.65, -0.90; p = .002), severity (-3.03, 95% CI: -3.65, -2.40; p ≤ .001), duration (-7.67, 95% CI: -11.47, -3.90; p ≤ .001), and frequency (-5.42, 95% CI: -7.31, -3.53; p ≤ .001) after eight weeks [38]. These findings suggest that co-administration of CoQ10/L-carnitine supplements results in the improvement of severity, duration, and frequency of migraine attacks [38].…”

Section: L-carnitinementioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Implications of Altered Energy Metabolism in Migraine: A State-of-the-Art Review

Hassan

Farooque

Choudhry

et al. 2020

Cureus

View full text Add to dashboard Cite

Currently, the management strategies aimed at the resolution of migraine are pharmacological. Most of these therapies are known to alter the serotonin balance of the brain. Furthermore, therapies blocking the calcitonin gene-related peptide (CGRP) have also proven to be quite effective in their treatments. However, apart from being expensive, these therapies do not influence premonitory and aura symptoms. This suggests an incomplete approach and an inadequate understanding of the migraine pathophysiology. Recent metabolic studies have indicated that migraine should be considered as an adaptive response to the mismatch between the cerebral energy reserves and expenditure. Therefore, understanding the underlying metabolism helps derive possible novel therapeutic modalities for migraines. In this review, we highlight the underlying metabolic abnormalities found in migraine patients. This will form the basis of our evidence-based discussion on metabolic therapeutic options for migraines.

show abstract

Section: L-carnitinementioning

confidence: 99%

Section: L-carnitinementioning

confidence: 99%

Section: L-carnitinementioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Implications of Altered Energy Metabolism in Migraine: A State-of-the-Art Review

Hassan

Farooque

Choudhry

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…The participants were asked to complete their headache diaries during the upcoming month [19]. The VAS questionnaire was used to assess the severity of headache [20]. Based on this scale, the headache severity is ranked from 0 to 10, with "0" indicating no pain and "10" the worst imaginable pain.…”

Section: Assessments Of Migraine Clinical Featuresmentioning

confidence: 99%

24-h Urinary Sodium and Potassium and Their Association with Clinical Features of Migraine Headache

Arab

Khorvash

Heidari

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Aim: There is a paucity of evidence regarding the association between sodium and potassium with migraine. To explore the possible relationship between 24-h urinary sodium and potassium with clinical features of migraine patients, we conducted a cross-sectional study using a sample of the Iranian population. Methods: In this cross-sectional study, 262 participants aged 20-50 years, with a diagnosis of migraine were included. One 24-h urine sample was collected by each subject to estimate sodium and potassium intake. Clinical features of migraine including frequency, duration, severity, migraine headache index score (MHIS), and headache impact test (HIT) were assessed. The serum nitric oxide values were assessed using the Griess method. Multiple linear regression analysis was used and beta (β) and 95% corresponding confidence interval (CI) were reported. Results: The 24-h urinary sodium was significantly associated with frequency (Model 3: β=1.86, 95%CI (0.10, 3.62); P=0.038), duration (Model 2: β=0.38, 95%CI (0.11, 0.66); P=0.006) and MHIS (Model 3: β=0.19, 95%CI (0.01, 0.37); P=0.034). Also, there was a significant association between Na/K ratio and MHIS (Model 2: β=0.16, 95%CI (0.003, 0.33); P=0.045). There was no significant relationship between 24-h urinary potassium and any of the intended variables (all P values <0.05). Conclusion: Our findings suggest that reducing sodium intake and increasing potassium intake could be used as a useful and novel approach to improve clinical findings of migraine and associated burden of disease. Additional studies are needed to replicate these findings and to discover mechanisms that mediate the association between sodium and potassium intake with migraine headache.

show abstract

“…Further support for a link to energy metabolism and / or mitochondrial functioning comes from the migraine preventative effect of several nutraceuticals (22), such as riboflavin at high dose (200-400mg/ day) (23)(24)(25)(26)(27)(28)(29); coenzyme Q10 (400mg capsules or 300mg liquid suspension) (30)(31)(32)(33)(34)(35), magnesium (36) and alpha-lipoic acid (ALA; 600mg) (37)(38)(39). Dietary approaches, such as a ketogenic diet (KD), which promotes the hepatic production of an alternative energy substrate for the brain and to some extent mimics the state of fasting, have been shown to be migraine protective (40)(41)(42)(43)(44)(45) (see (46) for potential mechanism of ketosis in migraine).…”

Section: Introductionmentioning

confidence: 99%

Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine

Gross

Putananickal²,

Orsini³

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction Increasing evidence points towards the role of mitochondrial functioning, energy metabolism, and oxidative stress in migraine. However not all previous research has been conclusive and some mitochondrial function / oxidative stress markers have not yet been examined. Methods To this end, alpha-lipoic acid (ALA), total thiols, total plasma antioxidant capacity (TAC), lipid peroxide (PerOx), oxidised LDL (oxLDL), HbA1c and lactate were determined in the serum of 32 higher frequency episodic migraineurs (5-14 migraine days/ months, 19 with aura, 28 females) in this cross-sectional study. Results The majority of patients had abnormally low ALA and lactate levels (87.5% and 78.1%, respectively). 46.9% of the patients had abnormally high PerOx values, while for thiols and TAC over one third of patients had abnormally low values (31.2% and 37.5%, respectively). 21.9% of patients had abnormally low HbA1c and none had an HbA1c level above 5.6%. oxLDL was normal in all but one patient. Discussion This study provides further evidence for a role of oxidative stress and altered metabolism in migraine pathophysiology, which might represent a suitable therapeutic target. ALA, being too low in almost 90% of patients, might represent a potential biomarker for migraine. Further research is needed to replicate these results, in particular a comparison with a control group. This study is part of the trial registration: ClinicalTrials.gov: NCT03132233, registered on 27.04.2017, https://clinicaltrials.gov/ct2/show/NCT03132233

show abstract

The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial

Cited by 57 publications

References 26 publications

Therapeutic Implications of Altered Energy Metabolism in Migraine: A State-of-the-Art Review

Therapeutic Implications of Altered Energy Metabolism in Migraine: A State-of-the-Art Review

24-h Urinary Sodium and Potassium and Their Association with Clinical Features of Migraine Headache

Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine

Contact Info

Product

Resources

About